PhytoMedical Technologies, Inc. today announced that research and development of the Company's proprietary BDC-03 compound has been expanded to include investigations of High Density Lipoproteins (HDL), shown in a study to be favorably elevated by BDC-03. The results of an initial animal study showed that BDC-03 has pharmacologically active elements that have the potential to reduce body fat percentage, lower cholesterol, and most importantly, increase lean muscle.
Business Wire
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
NHS England Picks Up Glucose Monitors for Type 1 Diabetes Patients
The devices are now available on prescription for all patients that qualify through NHS’ clinical guidelines.
FDA Expands Approval of Bristol-Myers Squibb’s Empliciti
EPd is the first triplet combination approved based on a randomized clinical trial using pomalidomide and dexamethasone as comparators.
FDAnews Drug Daily Bulletin
PHYTOMEDICAL'S BDC-O3 COMPOUND SHOWN TO ELEVATE HDL, 'GOOD' CHOLESTEROL
May 17, 2006
